Evaluation of adjuvant chemoradiation therapy for ampullary adenocarcinoma: The Johns Hopkins Hospital - Mayo Clinic collaborative study

Radiation Oncology

Volumn 6, Issue 1, 2011, Pages

  Narang, Amol K ^a   Miller, Robert C ^b   Hsu, Charles C ^a,c   Bhatia, Sumita ^b   Pawlik, Timothy M ^a   Laheru, Dan ^a   Hruban, Ralph H ^a   Zhou, Jessica ^a   Winter, Jordan M ^a   Haddock, Michael G ^b   Donohue, John H ^b   Schulick, Richard D ^a   Wolfgang, Christopher L ^a   Cameron, John L ^a   Herman, Joseph M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adjuvant; Ampullary; Carcinoma; Chemoradiation; Resectable

Indexed keywords

FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; BODY WEIGHT LOSS; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EPIGASTRIC PAIN; FATIGUE; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERITONEUM METASTASIS; SEPSIS; SURVIVAL ANALYSIS; SURVIVAL RATE; SURVIVAL TIME; VATER PAPILLA CARCINOMA; ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; BILE DUCT TUMOR; CHEMORADIOTHERAPY; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; METASTASIS; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES; VATER PAPILLA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AMPULLA OF VATER; ANTINEOPLASTIC AGENTS; CHEMORADIOTHERAPY; CHEMOTHERAPY, ADJUVANT; COMMON BILE DUCT NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MARYLAND; MIDDLE AGED; MINNESOTA; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, CONFORMAL; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 80053357684     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717x-6-126     Document Type: Article

References (37)

1. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML, Grochow LB, Abrams RA: Six hundred fifty consecutive pancreaticoduodenectomies in the 1990s. Pathology, complication and outcomes. Ann Surg 1997, 226:248-260
2. Bouvet M, Gamagami RA, Gilpin EA, Romeo O, Sasson A, Easter DW, Moossa AR: Factors influencing survival after resection for periampullary neoplasms. Am J Surg 2000, 180:13-17
3. Stephens J, Kuhn J, O'Brien J, Preskitt J, Derrick H, Fisher T, Fuller R, Lieberman Z: Surgical morbidity, mortality, and long term survival in patients with pancreatic cancer following pancreaticoduodenectomy. Am J Surg 1997, 174:600-604
4. Kalser MH, Ellenberg SS: Pancreatic cancer: adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985, 120:899-903
5. Matory YL, Gaynor J, Brennan M: Carcinoma of the ampulla of Vator. Surg Gynecol Obstet 1993, 177:366-370
6. Monson JR, Donohue JH, McEntee GP, McIlrath DC, van Heerden JA, Shorter RG, Nagorney DM, Ilstrup DM: Radical resection for carcinoma of the ampulla of Vater. Arch Surg 1991, 126:353-357
7. Talamini MA, Moesinger RC, Pitt HA, Sohn TA, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL: Adenocarcinoma of the ampulla of Vater: a 28-year experience. Ann Surg 1997, 225:590-600
8. De Castro SM, Kuhlmann KF, van Heek NT, Busch OR, Offerhaus GJ, van Gulik TM, Obertop H, Gouma DJ: Recurrent disease after microscopically radical (R0) resection of periampullary adenocarcinoma in patients without adjuvant therapy. J Gastrointest Surg 2004, 8:775-784
9. Howe JR, Klimstra DS, Moccia RD, Conlon KC, Brennan MF: Factors predictive of survival in ampullary carcinoma. Ann Surg 1998, 228:87-94
10. Brown KM, Tompkins AJ, Yong S, et al: Pancreaticoduodenectomy is curative in the majority of patients with node negative ampullary cancer. Arch Surg 2005, 140:529-533
11. El-Ghazzawy AG, Wade TP, Virgo KS, Johnson FE: Recent experience with the cancer of the ampulla of Vater in a national hospital group. Am Surg 1995, 61:607-611
12. Klempnauer J, Ridder GJ, Pichlmayr R: Prognostic factors after resection of ampullary carcinoma: Multivariate survival analysis in comparison with ductal cancer of the pancreatic head. Br J Surg 1995, 82:1686-1691
13. Gastrointestinal Tumor Study Group: Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987, 59:2006-2010
14. Klinkenbijl JH, Jeekel J, Sahmoud T, van Pel R, Couvreur ML, Veenhof CH, Arnaud JP, Gonzalez DG, de Wit LT, Hennipman A, Wils J: Adjuvant radiotherapy and 5-Fluorouracil after curative resection of cancer of the pancreas and periampullary region. Phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 1999, 230:776-784
15. Krishnan S, Rana V, Evans DB, Varadhachary G, Das P, Bhatia S, Delclos ME, Janjan NA, WolffRA, Crane CH, Pisters PW: Role of adjuvant chemoradiation therapy in adenocarcinomas of the ampulla of vater. Int J Radiat Oncol Biol Phys 2008, 70:735-743
16. Bhatia S, Miller RC, Haddock MG, Donohue JH, Krishnan S: Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys 2006, 66:514-519
17. Zhou J, Hsu CC, Winter JM, Pawlik TM, Laheru D, Hughes MA, Donehower R, Wolfgang C, Akbar U, Schulick R, Cameron J, Herman JM: Adjuvant chemoradiation versus surgery alone for adenocarcinoma of the ampulla of Vater. Radiotherapy and Oncology 2009, 92:244-248
18. Horowitz DP, Hsu CC, Wang J, Makary MA, Winter JM, Robinson R, Schulick RD, Cameron JL, Pawlik TM, Herman JM: Adjuvant chemoradiation therapy after pancreaticoduodenectomy in elderly patients with adenocarcinoma. Int J Radiat Oncol Biol Phys
19. Winter JM, Cameron JL, Olino K, Herman JM, de Jong MC, Hruban RH, Wolfgang CL, Eckhauser F, Edil BH, Choti MA, Schulick RD, Pawlik TM: Clinicopathologic analysis for ampullary neoplasms in 450 patients: implications for surgical strategy and long-term prognosis. J Gastrointest Surg 2010, 14:379-387
20. Kopelson G: Curative surgery for adenocarcinoma of the pancreas/ampulla of Vater: the role of adjuvant pre or postoperative radiation therapy. Int J Radiat Oncol Biol Phys 1983, 9:911-915
21. Kopelson G, Galdabini J, Warshaw AL, Gunderson LL: Patterns of failure after curative surgery for extra-hepatic biliary tract carcinoma: Implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 1981, 7:413-417
22. Allema JH, Reinders ME, van Gulik TM, van Leeuwen DJ, Verbeek PC, de Wit LT, Gouma DJ: Results of pancreaticoduodenectomy for ampullary carcinoma and analysis of prognostic factors for survival. Surgery 1995, 117:247-253
23. Neoptolemos JP, Talbot IC, Shaw DC: Long-term survival after resection of ampullary carcinoma is associated independently with tumor grade and a new staging classification that assesses local invasiveness. Cancer 1988, 61:1403-1407
24. Beger HG, Treitschke F, Gansauge F, Harada N, Hiki N, Mattfeldt T: Tumor of the ampulla of Vater: experience with local or radical resection in 171 consecutively treated patients. Arch Surg 1999, 134:526-532
25. Yeo CJ, Sohn TA, Cameron JL, Hruban RH, Lillemoe KD, Pitt HA: Periampullary adenocarcinoma: analysis of 5-year survivors. Ann Surg 1998, 227:821-831
26. Duffy JP, Hines OJ, Liu JH, Ko CY, Cortina G, IsacoffWH, Nguyen H, Leonardi M, Tompkins RK, Reber HA: Improved survival for adenocarcinoma of the ampulla of Vater: fifty-five consecutive resections. Arch Surg 2003, 138:941-948
27. Hsu HP, Yang TM, Hsieh YH: Predictors for patterns of failure after pancreaticoduodenectomy in ampullary cancer. Ann Surg Oncol 2007, 14:50-60
28. Delcore R Jr, Connor CS, Thomas JH, Friesen SR, Hermreck AS: Significance of tumor spread in adenocarcinoma of the ampulla of Vater. Am J Surg 1989, 158:593-596
29. Shutze WP, Sack J, Aldrete JS: Long-term follow-up of 24 patients undergoing radical resection for ampullary carcinoma, 1953 to 1988. Cancer 1990, 66:1717-1720
30. O'Connell JB, Maggard MA, Manunga J Jr, Tomlinson JS, Reber HA, Ko CY, Hines OJ: Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Onc 2008, 15:1820-1827
31. Willett CG, Warshaw AL, Convery K, Compton CC: Patterns of failure after pancreaticoduodenectomy for ampullary carcinoma. Surg Gynecol Obstet 1993, 176:33-38
32. Mehta VK, Fisher GA, Ford JM, Poen JC, Vierra MA, Oberhelman HA, Bastidas AJ: Adjuvant chemoradiotherapy for ''unfavorable'' carcinoma of the ampulla of Vater: Preliminary report. Arch Surg 2001, 136:65-69
33. Lee JH, Whittington R, Williams NN, Berry MF, Vaughn DJ, Haller DG, Rosato EF: Outcome of pancreaticoduodenectomy and impact of adjuvant therapy for ampullary carcinomas. Int J Radiat Oncol Biol Phys 2000, 47:945-953
34. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K, Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner E, Schmalenberg H, Weigang-Koehler K, Bechstein WO, Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess H: Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer. JAMA 2007, 297:267-277
35. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer 2002, 95:1685-1695
36. Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, Mcdonald A, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Coxon FY, Lacaine F, Middleton MR, Ghaneh P, Bassi C, Halloran C, Olah A, Rawcliffe CL, Büchler MW: Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater [abstract]. J Clin Oncol 2011, 29, abstr LBA4006
37. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, Madhusudan S, Iveson T, Hughes S, Pereira SP, Roughton M, Bridgewater J: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010, 14:1273-1281